CURAPATH
LIVE

Serial Number

97534202

Owner

Polypeptide Therapeutic Solutions USA LLC

Attorney

Julie R. Fenstermaker

First Use Date

Oct 17, 2022

Filing Date

Aug 4, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CURAPATH Trademark

Serial Number: 97534202 • Registration: 7779108

CURAPATH is a trademark filed by Polypeptide Therapeutic Solutions USA LLC on August 4, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Polypeptide Therapeutic Solutions USA LLC

Suite 3460
San Francisco, CA 94111

Entity Type: 16

Trademark Details

Filing Date

August 4, 2022

Registration Date

April 29, 2025

First Use Anywhere

October 17, 2022

First Use in Commerce

October 17, 2022

Published for Opposition

January 2, 2024

Goods & Services

Custom manufacture of polyamino acid based and nanoparticle based biopharmaceutical preparations for purposes of scientific and medical research and for therapeutic purposes

Biopharmaceutical preparations, namely, polyamino acid based therapeutics, polymer, and lipid based pharmaceutical preparations for the treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, genetic and immune system related diseases and disorders

Regulatory compliance consulting services in the biotechnology fields, namely, reviewing standards and practices and assisting third parties with compliance with governmental laws, regulations and rules pertaining to medical devices, medical technologies, medications, biopharmaceuticals, and biotechnology

Consulting services in the fields of biotechnology, pharmaceutical research and development of polyamino acid based and nanoparticle molecules for research, drug, vaccine, and therapeutic product use; product research and development for use in manufacturing of polyamino acid based and nanoparticle molecules; quality management services, namely, quality evaluation and analysis, quality assurance and quality control in the field of biotechnology and polyamino acid based and nanoparticle molecules

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Apr 29, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Apr 29, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Apr 7, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 7, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Apr 2, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 2, 2025 AITU
USE AMENDMENT FILED
Jan 23, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Jan 23, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 23, 2024 EXRA
SOU EXTENSION 1 GRANTED
Aug 23, 2024 EX1G
SOU EXTENSION 1 FILED
Aug 23, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 23, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 27, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 2, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jan 2, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 13, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 27, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 20, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 18, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 18, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 25, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 25, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 25, 2023 CNRT
ASSIGNED TO EXAMINER
May 23, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 25, 2022 NWOS
NEW APPLICATION ENTERED
Aug 8, 2022 NWAP